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Reply
We thank Fatkin and Feneley for their interest in our report (1). The
main point of the study was that integrated backscatter provides an
objective measure of spontaneous echo contrast (SEC) that correlates
well with qualitative grading and with clinical and echocardiographic
variables of thromboembolism. They express concern with our premise
that the traditional qualitative grading of SEC (2,3) is neither objective
nor reproducible relative to the proposed method of quantification of
SEC.
Fatkin and Feneley point to the “good” agreement (kappa value
0.65) in the qualitative grading of SEC reported by Kronik et al. (4). In
that study, the kappa value reflects the off-line interobserver variability
(i.e., variability in the interpretation by two observers of videotape
images generated by a single observer). In fact, there was disagreement
in the grading in 17% of cases, probably an unacceptably high
proportion. True interobserver variability critically includes not only
differences in image interpretation, but also variability resulting from
different image acquisition, including the effect of imaging planes, gain
and depth settings. It may also include the reported intermachine
variability in the detection of SEC among different commercial echo-
cardiographic machines (5).
A more recent study (6) further highlights the variability in
interpretation of SEC. The Stroke Prevention in Atrial Fibrillation
(SPAF) Investigators (6), reported kappa values ranging from 0.47 to
0.67 for the detection and grading of SEC in the left atrium or left
atrial appendage by 20 highly experienced echocardiographers, using
preacquired videotape images and a manual of operations.
The comparison between SEC grade and integrated backscatter
intensities in our report reflect true interobserver reliability because it
involved data that were derived from separate acquisitions and sepa-
rate interpretations. The integrated backscatter image sequence was
obtained after the transesophageal echocardiographic study using its
own calibration system and was analyzed using the acoustic densitom-
etry system in blinded manner by a technician who had no knowledge
of the qualitative grade (1).
Fatkin and Feneley have developed a SEC grading system using
five grades (7) and have shown an interobserver variability of 6% and
a good correlation with off-line videodensitometry. That study involved
a videodensitometric scoring of the same image from which the
qualitative grade was derived. The videodensitometric scoring is
affected by a nonlinearity of the ultrasound signal that includes the
effects of log compression and postprocessing that develops the
two-dimensional image in commercial echocardiographic machines
(1). Furthermore, their proposed grading system may work in very
experienced hands within the same laboratory, but we believe that
training and experience are important in obtaining good agreement in
qualitative grading systems. Conversely, we believe that operator
experience has relatively less effect on variability in the digital acqui-
sition and analysis of SEC by integrated backscatter, provided that the
operator properly calibrates the backscatter intensity of the image as
outlined in our report (1). One of the remarkable features of the
integrated backscatter system is that the software digitally documents,
on an optical disk, all the crucial system settings, such as gain and
compression. The clear benefit is that the clinician can set up the
system identically, thereby enhancing reproducibility and accuracy in
serial studies on the same patient.
Fatkin and Feneley point out some potential pitfalls in using SEC
to predict thromboembolic risk in patients with atrial fibrillation. In
their study (8), they found that SEC did not predict embolic events
reliably, especially in an anticoagulated population. This finding is in
contrast to the study by Leung et al. (9) who showed that patients with
SEC have a higher risk of developing stroke or embolic events
(12%/year vs. 3%/year) than patients without SEC. Of note, 34% of
patients with SEC were receiving anticoagulant therapy in that study.
Those embolic event rates were used as assumptions in the sample size
estimate of 350 patients for our ongoing prospective multicenter study
using integrated backscatter. The cost of recruiting patients and the
availability of the software may not be so limiting because the
integrated backscatter software system is now commercially available
from the manufacturer.
We agree with Fatkin and Feneley on the importance of establish-
ing a clinically important cutoff for the severity of SEC, above which
prophylactic anticoagulation should be recommended. A major objec-
tive of a multicenter trial would be to establish a clinical relevant
“cutoff” value from the continuous integrated backscatter data. It is
not known whether these clinically relevant cutoff values may be the
same as the arbitrary divisions that now exist between qualitative
grades.
We concur that the currently used qualitative grading of SEC may
be adequate for the majority of clinical studies. However, we maintain
that assigning a qualitative grade to a continuous variable such as SEC
inherently involves some element of subjectivity, and the technical
aspects of image acquisition can introduce additional variability. For
these reasons, we believe that a method to quantify SEC is a necessary
pursuit to objectively validate the significance and potential clinical
value of this phenomenon.
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Risk for Sudden Cardiac Death Associated
With Marathon Running
As an avid runner and occasional marathoner, I was pleased to learn
that the risk of sudden death during or immediately after running a
marathon is very low (1). Unfortunately, I believe that the authors’
assessment of risk relative to other activities is somewhat misleading.
Assuming that there are 200,000,000 U.S. adults at risk for sudden
death, and that there are 500,000 sudden deaths annually, the risk of
sudden death or cardiac arrest as a function of living hours is
approximately 1 death/3,504,000 h. The rate reported by Maron et al.
(1) during or after a marathon, 1 death/215,000 h, is roughly 16-fold
higher than the rate during normal living.
Thus, although the risk of dying suddenly during a marathon is
quite low, it is still 16 times greater than the risk of sudden death
during all other living activities combined.
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We thank Rich for his comments. We certainly agree, based on our
recently published data (1), that the risk for sudden death directly
associated with long-distance or marathon running is indeed exceed-
ingly low (i.e., ;1 in 50,000). However, calculation of the overall risk
for premature death associated with living can prove to be a rather
complex and difficult undertaking. In our report (1) we chose to
calculate such values directly from U.S. Vital Statistics and the
National Center for Health Statistics for the years 1979, 1990 and 1991
(2). Perhaps this methodology accounts for the differences between
our published values (1) and the estimates offered by Rich in his letter.
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Late Potentials in the Thrombolytic Era:
Time for Reevaluation?
We read with interest the report by Karam et al. (1). The authors
reported a decrease in the prevalence of late potentials with mechan-
ical reperfusion compared with thrombolysis after myocardial infarc-
tion. However, the report raises a number of important issues.
Although the significance of late potentials in the early phase
(,48 h) is unclear, El-Sherif et al. (2) found that only late potentials
recorded between days 6 and 30 were associated with arrhythmic
events. In particular, they recommended that “the optimal time
window for obtaining a signal-averaged ECG is between 6 and 14 days
after infarction.” However, the study by El-Sherif et al. predated the
thrombolytic era and excluded patients .79 years old. Although
Karam et al. justify their recording time on this study, they give only
the median time and neglect to give the range. A median recording
time of 11 days suggests that many recordings may have been made
after day 14, at which time late potentials have little prognostic
significance. Furthermore, the authors fail to give any data on arrhyth-
mic events or sudden death in the patients studied.
This leads to a more fundamental issue, which is the unproved role
of late potentials as a predictor of arrhythmic events in a thrombolyzed
cohort. Many of the pioneering studies referenced in the report
predate the thrombolytic era. The widespread use of thrombolysis and
early revascularization have significantly reduced the arrhythmic event
and mortality rates after acute myocardial infarction (3,4). These same
studies (neither of which is referenced) have failed to show a relation
between late potential development and arrhythmic events in a
thrombolyzed patient cohort.
We previously showed (5) that late potentials in the first 7 days
after acute anterior myocardial infarction (after thrombolysis) are
associated with an increase in ventricular volume at 6 weeks. In a
larger study of patients receiving thrombolyic therapy, Hohnloser et al.
(4) also found that late potentials were associated with wall motion
abnormalities. On the basis of our findings, we suggested that the
prognostic value of late potentials in the first week (and particularly on
day 3) may be related to ventricular dilation. Although Karam et al.
performed radionuclide left ventricular angiography in all patients, no
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